Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 randomized double-blind sham-controlled study of intravitreal QPI-1007 for non-arteritic anterior ischemic optic neuropathy
MOH_2017-03-16_000198Phase 3Active, not recruiting
- Sponsor
- Quark Pharmaceuticals
- Start
- May 2016
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of QPI-1007 in non-arteritic anterior ischemic optic neuropathy (NAION) (5 arms), sponsored by Quark Pharmaceuticals. Primary endpoint: Visual acuity preservation. Started May 2016; status: active, not recruiting.
02
Drugs
QPI-1007
03
Conditions
non-arteritic anterior ischemic optic neuropathy (NAION)
Beyond the preview
Go deeper on MOH_2017-03-16_000198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-16_000198.